{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:52:26Z","timestamp":1789537946741,"version":"build-2803163510"},"reference-count":72,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Translational Research Implementation Fund from the University of Alberta\u2019s Department of Medicine","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Translational Research Implementation Fund 2024"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The immune landscape plays an important role in various pituitary diseases, ranging from hypophysitis to pituitary neuroendocrine tumors. Moreover, the use of immune checkpoint inhibitors (ICIs) has dramatically altered the landscape of cancer treatment by improving prognosis and overall survival in a multitude of advanced-staged malignancies, though their use in pituitary neuroendocrine tumors has remained limited. In this review, we will focus on selected topics to highlight the impact of the immune microenvironment on the function of the pituitary gland, namely, animal models of autoimmune hypophysitis, including ICI-induced hypophysitis as a common adverse event, and the importance of its early recognition in patients treated with ICIs. Using a case, we will provide an overview on the epidemiology, pathogenesis, clinical spectrum, diagnosis, predictors, and management of ICI-induced hypophysitis. We will also summarize the role of the immune microenvironment in pituitary neuroendocrine tumors with programmed cell death ligand 1 as a biomarker for treatment. Lastly, we will review the role of ICIs in the management of 40 patients with aggressive and metastatic pituitary neuroendocrine tumors. Current knowledge gaps in these topics will also be highlighted.<\/jats:p>","DOI":"10.3390\/cells14181450","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T14:31:41Z","timestamp":1758033101000},"page":"1450","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Pituitary Immune Environment and Immunotherapy: From Hypophysitis to Pituitary Neuroendocrine Tumors"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7993-4727","authenticated-orcid":false,"given":"Toru","family":"Tateno","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, AB T6G 2G3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4181-2940","authenticated-orcid":false,"given":"Mariam","family":"Shahidi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, AB T6G 2G3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1945-5569","authenticated-orcid":false,"given":"Jian-Qiang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9609-0896","authenticated-orcid":false,"given":"Constance","family":"Chik","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, AB T6G 2G3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Di Stasi, V., La Sala, D., Cozzi, R., Scavuzzo, F., De Geronimo, V., Poggi, M., Vitale, M., and Tortora, A. (2025). Immunotherapy-Related Hypophysitis: A Narrative Review. Cancers, 17.","DOI":"10.3390\/cancers17030436"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"bqae084","DOI":"10.1210\/endocr\/bqae084","article-title":"Pituitary Complications of Checkpoint Inhibitor Use","volume":"165","author":"Faje","year":"2024","journal-title":"Endocrinology"},{"key":"ref_4","unstructured":"(2025, April 30). Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-cosibelimab-ipdl-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma."},{"key":"ref_5","unstructured":"(2025, April 30). Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-tevimbra."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1272\/jnms.JNMS.2023_90-215","article-title":"Immune Checkpoint Inhibitors and Associated Pituitary Dysfunctions: A Mini-Review","volume":"90","author":"Fukuda","year":"2023","journal-title":"J. Nippon Med. Sch."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"104595","DOI":"10.1016\/j.critrevonc.2024.104595","article-title":"Central nervous system complications of immune checkpoint inhibitors: A comprehensive review","volume":"206","author":"Lopes","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MED.0000000000000652","article-title":"Hypophysitis from immune checkpoint inhibitors: Challenges in diagnosis and management","volume":"28","author":"Kotwal","year":"2021","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/er.2004-0011","article-title":"Autoimmune hypophysitis","volume":"26","author":"Caturegli","year":"2005","journal-title":"Endocr. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1210\/en.2007-1692","article-title":"Autoimmune hypophysitis of SJL mice: Clinical insights from a new animal model","volume":"149","author":"Tzou","year":"2008","journal-title":"Endocrinology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1210\/en.2011-1004","article-title":"From pituitary expansion to empty sella: Disease progression in a mouse model of autoimmune hypophysitis","volume":"152","author":"Lupi","year":"2011","journal-title":"Endocrinology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"J88","DOI":"10.1016\/j.jaut.2011.07.001","article-title":"Placenta suppresses experimental autoimmune hypophysitis through soluble TNF receptor 1","volume":"38","author":"Rose","year":"2012","journal-title":"J. Autoimmun."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lin, H.H., Gutenberg, A., Chen, T.Y., Tsai, N.M., Lee, C.J., Cheng, Y.C., Cheng, W.H., Tzou, Y.M., Caturegli, P., and Tzou, S.C. (2017). In situ activation of pituitary-infiltrating T lymphocytes in autoimmune hypophysitis. Sci. Rep., 7.","DOI":"10.1038\/srep43492"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.4049\/jimmunol.2001073","article-title":"Th17 cells contribute to the pathology of autoimmune hypophysitis","volume":"206","author":"Chalan","year":"2021","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Huang, H.C., Chen, Y.T., Lin, H.H., Li, Z.Q., Yang, J.M., and Tzou, S.C. (2022). Inhibition of IRAK1 is an effective therapy for autoimmune hypophysitis in mice. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314958"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Mihic-Probst, D., Reinehr, M., Dettwiler, S., Kolm, I., Britschgi, C., Kudura, K., Maggio, E.M., Lenggenhager, D., and Rushing, E.J. (2020). The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events. Imunobiology, 225.","DOI":"10.1016\/j.imbio.2020.152009"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"E946","DOI":"10.1210\/jc.2014-4209","article-title":"Rabphilin-3A as a Targeted Autoantigen in Lymphocytic Infundibulo-neurohypophysitis","volume":"100","author":"Iwama","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Arihara, Z., Sakurai, K., Niitsuma, S., Sato, R., Yamada, S., Inoshita, N., Iwata, N., Fujisawa, H., Watanabe, T., and Suzuki, A. (2022). Studies on anti-rabphilin-3A antibodies in 15 consecutive patients presenting with central diabetes insipidus at a single referral center. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-08552-y"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/path.5046","article-title":"Critical role of rabphilin-3A in the pathophysiology of experimental lymphocytic neurohypophysitis","volume":"244","author":"Yasuda","year":"2018","journal-title":"J. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7925","DOI":"10.1007\/s00432-023-04659-5","article-title":"Immune checkpoint inhibitor-induced hypophysitis: Clinical and biochemical features","volume":"149","author":"Rosinha","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cardona, Z., Sosman, J.A., Chandra, S., and Huang, W. (2023). Endocrine side effects of immune checkpoint inhibitors. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1157805"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11102-021-01182-z","article-title":"Differences between immunotherapy-induced and primary hypophysitis-a multicenter retrospective study","volume":"25","author":"Amereller","year":"2022","journal-title":"Pituitary"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"22246","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.beem.2022.101663","article-title":"The novel concept of \u201cOnco-Immuno-Endocrinology\u201d led to the discovery of new clinical entity \u201cparaneoplastic autoimmune hypophysitis\u201d","volume":"36","author":"Takahashi","year":"2022","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1210\/clinem\/dgab672","article-title":"Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease","volume":"107","author":"Langlois","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1093\/ejendo\/lvad179","article-title":"Clinical features of anti-pituitary-specific transcription factor-1 (PIT-1) hypophysitis: A new aspect of paraneoplastic autoimmune condition","volume":"190","author":"Urai","year":"2024","journal-title":"Eur. J. Endocrinol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/cen.15075","article-title":"Pituitary-related immune adverse events induced by programmed death Protein-1 inhibitors differ clinically from hypophysitis","volume":"101","author":"Yang","year":"2024","journal-title":"Clin. Endocrinol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab associated hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12020-024-03949-3","article-title":"Immune checkpoint inhibitor-associated new-onset hypophysitis: A retrospective analysis using the FAERS","volume":"86","author":"Lu","year":"2024","journal-title":"Endocrine"},{"key":"ref_32","first-page":"dgaf122","article-title":"The Risk of Adrenal Insufficiency after Treatment with Relatlimab in Combination with Nivolumab is Higher than Expected","volume":"26","author":"Faje","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100683","DOI":"10.1016\/j.modpat.2024.100683","article-title":"Frequency and Consequences of Immune Checkpoint Inhibitor-Associated Inflammatory Changes in Different Organs: An Autopsy Study Over 13-Years","volume":"38","author":"Maccio","year":"2025","journal-title":"Mod. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101668","DOI":"10.1016\/j.beem.2022.101668","article-title":"Immune checkpoint inhibitor-related hypophysitis","volume":"36","author":"Mizukoshi","year":"2022","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s11102-021-01141-8","article-title":"Isolated ACTH deficiency induced by cancer immunotherapy: A systematic review","volume":"24","author":"Iglesias","year":"2021","journal-title":"Pituitary"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: A 10-year assessment","volume":"14","author":"Ippolito","year":"2019","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e000779","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: A prospective study","volume":"8","author":"Kobayashi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e002493","DOI":"10.1136\/jitc-2021-002493","article-title":"Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors","volume":"9","author":"Kobayashi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mitri, F., Machiraju, D., Naoum, C., and Hassel, J.C. (2024). Early Serum Markers for Immune Checkpoint Inhibitor Induced Hypophysitis in Melanoma Patients. Cancers, 16.","DOI":"10.3390\/cancers16071340"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11102-018-0866-6","article-title":"Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis","volume":"21","author":"Sheriff","year":"2018","journal-title":"Pituitary"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40618-020-01297-3","article-title":"Predicting development of ipilimumab-induced hypophysitis: Utility of T4 and TSH index but not TSH","volume":"44","author":"Siddiqui","year":"2021","journal-title":"J. Endocrinol. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1159\/000539345","article-title":"The Role of Programmed Cell Death Ligand 1 Expression in Pituitary Tumours: Lessons from the Current Literature","volume":"114","author":"Silva","year":"2024","journal-title":"Neuroendocrinology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12022-015-9383-6","article-title":"Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas","volume":"26","author":"Lu","year":"2015","journal-title":"Endocr. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lopes-Pinto, M., Lacerda-Nobre, E., Silva, A.L., and Marques, P. (2024). Therapeutical Usefulness of PD-1\/PD-L1 Inhibitors in Aggressive or Metastatic Pituitary Tumours. Cancers, 16.","DOI":"10.3390\/cancers16173033"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3949\/ccjm.90a.22032","article-title":"Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management","volume":"90","author":"Kennedy","year":"2023","journal-title":"Cleve. Clin. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"115584","DOI":"10.1016\/j.celrep.2025.115584","article-title":"Immune atlas of pituitary neuroendocrine tumors highlights endocrine-driven immune signature and therapeutic implication","volume":"44","author":"Guo","year":"2025","journal-title":"Cell Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s11060-023-04382-8","article-title":"Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): Increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset","volume":"163","author":"Luo","year":"2023","journal-title":"J. Neuro-Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Vela-Pati\u00f1o, S., Salazar, M.I., Taniguchi-Ponciano, K., Vadillo, E., Gomez-Apo, E., Escobar-Espa\u00f1a, A., Perez-Koldenkova, V., Bonifaz, L., Aguilar-Flores, C., and Marrero-Rodr\u00edguez, D. (2024). The Immune Microenvironment Landscape of Pituitary NeuroEndocrine Tumors, a Transcriptomic Approach. Genes, 15.","DOI":"10.3390\/genes15050531"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-024-01325-4","article-title":"Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage-tumor interaction axes among different lineages of pituitary neuroendocrine tumors","volume":"16","author":"Lin","year":"2024","journal-title":"Genome. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5300381","DOI":"10.1155\/2021\/5300381","article-title":"Immune Checkpoints: Therapeutic Targets for Pituitary Tumors","volume":"2021","author":"Nie","year":"2021","journal-title":"Dis. Markers."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.lungcan.2019.02.022","article-title":"Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)","volume":"130","author":"Hermans","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1758835920937972","DOI":"10.1177\/1758835920937972","article-title":"PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: Potential implications for use of immunotherapy in these patients: The GFPC 03-2017 \u201cEPNEC\u201d study","volume":"12","author":"Arpin","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2018.02.003","article-title":"PD-L1 expression in large cell neuroendocrine carcinoma of the lung","volume":"118","author":"Eichhorn","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.humpath.2017.10.003","article-title":"Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: A potential target for anti-PD-1\/PD-L1 therapy","volume":"70","author":"Roberts","year":"2017","journal-title":"Hum. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Cossu, G., La Rosa, S., Brouland, J.P., Pitteloud, N., Harel, E., Santoni, F., Brunner, M., Daniel, R.T., and Messerer, M. (2023). PD-L1 Expression in Pituitary Neuroendocrine Tumors\/Pituitary Adenomas. Cancers, 15.","DOI":"10.3390\/cancers15184471"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1210\/jc.2018-01347","article-title":"Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab","volume":"103","author":"Lin","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/CAD.0000000000000856","article-title":"Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab","volume":"31","author":"Caccese","year":"2020","journal-title":"Anti-Cancer Drugs"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Duhamel, C., Ilie, M.D., Salle, H., Nassouri, A.S., Gaillard, S., Deluche, E., Assaker, R., Mortier, L., Cortet, C., and Raverot, G. (2020). Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature. J. Pers. Med., 10.","DOI":"10.3390\/jpm10030088"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lamb, L.S., Sim, H.W., and McCormack, A.I. (2020). Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.576027"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e001532","DOI":"10.1136\/jitc-2020-001532","article-title":"Efficacy of pembrolizumab in patients with pituitary carcinoma: Report of four cases from a phase II study","volume":"8","author":"Majd","year":"2020","journal-title":"J. Immunother. Cancer."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-20-0151","article-title":"Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: A new emerging treatment?","volume":"184","author":"Sol","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1227\/neu.0000000000002024","article-title":"Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report","volume":"91","author":"Shah","year":"2022","journal-title":"Neurosurgery"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1530\/EJE-22-0647","article-title":"Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: A cohort study","volume":"187","author":"Ilie","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Feola, T., Carbonara, F., Verrico, M., Di Crescenzo, R.M., Gianno, F., Colonnese, C., Arcella, A., de Alcubierre, D., Tomao, S., and Esposito, V. (2022). Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art. Cancers, 14.","DOI":"10.3390\/cancers14174093"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/cen.14645","article-title":"Should pituitary carcinoma be treated using a NET-like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy","volume":"98","author":"Goichot","year":"2023","journal-title":"Clin. Endocrinol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Medina, E.J., Zohdy, Y.M., Porto, E., Revuelta Barbero, J.M., Bray, D., Maldonado, J., Rodas, A., Mayol, M., Morales, B., and Neill, s. (2023). Therapeutic response to pazopanib: Case report and literature review on molecular abnormalities of aggressive prolactinomas. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1195792"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"bvad114.1099","DOI":"10.1210\/jendso\/bvad114.1099","article-title":"Remarkable response of ACTH-secreting pituitary carcinoma to immune checkpoint inhibitors: A case report","volume":"7","author":"Park","year":"2023","journal-title":"J. Endocr. Soc."},{"key":"ref_71","first-page":"321","article-title":"Aggressive pituitary tumors and carcinomas: Medical treatment beyond temozolomide","volume":"49","author":"Carretti","year":"2024","journal-title":"Minerva Endocrinol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"dgaf178","DOI":"10.1210\/clinem\/dgaf178","article-title":"Immune checkpoint inhibitor therapy for aggressive pituitary neuroendocrine tumors","volume":"20","author":"Lin","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/18\/1450\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:16:52Z","timestamp":1763727412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/18\/1450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":72,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cells14181450"],"URL":"https:\/\/doi.org\/10.3390\/cells14181450","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]}}}